Inhaled nitric oxide therapy in a critically ill neonate with Ebstein's anomaly.
The successful use of nitric oxide (NO) inhalation in a critically ill neonate with Ebstein's anomaly of the tricuspid valve is reported for the first time. This use of inhaled NO therapy suggests a therapeutic intervention that directly addresses the pathophysiologic process of severe neonatal Ebstein's anomaly.
Bruckheimer
E
E
Section of Pediatric Cardiology, Yale University School of Medicine, New Haven, CT 06520, USA.
Bulbul
Z
Z
Pinter
E
E
Gailani
M
M
Kleinman
C S
CS
Fahey
J T
JT
D000280:Administration, Inhalation; D003422:Critical Care; D004437:Ebstein Anomaly / Q000503:physiopathology / Q000628:therapy*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007231:Infant, Newborn; D009569:Nitric Oxide / Q000008:administration & dosage*; D014261:Tricuspid Valve / Q000002:abnormalities / Q000503:physiopathology
D009569:Nitric Oxide